Apr 8, 2025 · Adagene is a Nasdaq listed, global, clinical-stage immunotherapy company redefining the discovery and design of antibodies to open new horizons in the treatment of …

Adagene’s purpose-built technology platforms have generated a pipeline of potential first or best in class therapeutic assets with unique MOAs.

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers.

Mar 24, 2025 · Adagene (NASDAQ: ADAG) is a publicly traded, global, clinical-stage biopharmaceutical company committed to transforming the discovery and development of …

5 days ago · Get a real-time Adagene Inc. (ADAG) stock price with an overview of financials, statistics, forecasts, charts and more.

6 days ago · Sanofi's rash of dealmaking has continued with a $2.5 billion tie-up with Chinese cancer immunotherapy biotech Adagene, focused on developing a new generation of safer …

Feb 27, 2025 · Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor …

Mar 16, 2021 · ADG126 is Adagene’s lead SAFEbody™ product candidate. The SAFEbody technology, developed using Adagene’s AI-powered platform, enables binding of an antibody …

Adagene Inc. (Nasdaq: ADAG) is a biotechnology company transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines …

Feb 27, 2025 · Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor …